Recent research highlights the potential of targeting CD38 in treating autoimmune and plasma cell-driven diseases. The study reviews clinical evidence and discusses emerging therapies that could reshape treatment approaches in these conditions.
targeting cd38 across autoimmune and plasma cell driven immune mediated diseases rationale clinical evidence and emerging therapeutic landscape
Original title: “Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape.”